Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 680 across all filing types
Latest filing 2022-06-15 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
ESOP/ESPS/SBEB Scheme
Share Issue/Capital Change Classification · 95% confidence The document is a notification addressed to stock exchanges about the allotment of equity shares following the exercise of Employee Stock Options (ESOP). It mentions the increase in issued share capital and references compliance with SEBI regulations. The content is an announcement of a capital change due to share allotment, not a full financial report or detailed analysis. The document length is short (1306 characters), and it does not contain financial statements or detailed financial data. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2022-06-15 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Investor Presentation Classification · 75% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of analyst and institutional investor meetings. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which pertains to disclosure of material events and information. The content is a schedule of upcoming investor meetings, not a financial report, earnings release, or any detailed presentation. It is an announcement related to investor relations activities, specifically the scheduling of meetings with analysts and institutional investors. This fits the category of Investor Presentation (IP) as it relates to investor communications and presentations, even though the document itself is a meeting schedule rather than the presentation content. The document length is short (1599 characters), and it does not contain financial data or detailed analysis, so it is not an Interim Report or Annual Report. It is not a Regulatory Filing (RNS) because it is a specific scheduled meeting notice rather than a general regulatory announcement. Therefore, the best fit is Investor Presentation (IP) with moderate confidence due to the nature of the content being related to investor meetings and presentations.
2022-06-13 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the schedule of analyst and institutional investor meetings. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which pertains to disclosure of material events. The content is about informing the exchanges and public about upcoming investor meetings, which is a type of investor relations communication. There is no financial data, no report attached or referenced as being published, and no detailed presentation or transcript included. The document is essentially an announcement of scheduled investor meetings, which fits the category of Investor Presentation (IP) as it relates to investor communications and meetings, but since it is only a schedule notice without detailed presentation content, it is best classified as Regulatory Filings (RNS) which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is short (1484 characters), and it is not a report publication announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2022-06-08 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Investor Presentation Classification · 90% confidence The document is a short notice informing stock exchanges about the schedule of an analyst/institutional investor meeting. It references regulatory compliance (SEBI Listing Obligations) and provides meeting details but does not contain any financial data, report content, or detailed presentation materials. It is an announcement of a meeting rather than the meeting materials or transcript itself. Therefore, it fits best under Investor Presentation (IP) category as it relates to investor communications, specifically scheduling of investor meetings.
2022-06-06 English
Related Party Transaction
Regulatory Filings Classification · 95% confidence The document is a disclosure of related party transactions for the half-year ended March 31, 2022, prepared in compliance with SEBI regulations. It contains detailed financial data on transactions between the company and related parties, including subsidiaries and key management personnel, with specific values and balances. The document is dated May 31, 2022, and is addressed to stock exchanges, indicating it is a regulatory disclosure. The content is focused on related party transactions rather than a full financial report or earnings release. Given the nature of the document as a regulatory disclosure of related party transactions, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. It is not an Annual Report, Interim Report, or Audit Report, nor is it a voting result or management change announcement. The document length (10,291 characters) and detailed financial data confirm it is not a brief announcement but a substantive regulatory filing.
2022-05-31 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of upcoming analyst and institutional investor meetings. It references regulatory compliance (SEBI Listing Obligations) and provides dates and types of meetings but does not contain any financial data, results, or detailed presentations. The document is short (1704 characters) and serves as an announcement of meetings rather than a report or transcript. Therefore, it fits best under Investor Presentation (IP) as it relates to investor communications, but since it only announces the schedule and does not contain the presentation itself, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a general regulatory announcement about investor meetings without substantive financial content or presentation materials.
2022-05-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.